Communiqués UCB

Actions

UCB

BE0003739530

Marché Fermé - Euronext Bruxelles Autres places de cotation 17:35:18 31/05/2024			Varia. 5j.	Varia. 1 janv.
128,6 ^EUR	+1,70 %		-0,66 %	+63,05 %

20/05	AVIS D'ANALYSTES DU JOUR : Scor, Ubisoft, Nvidia, Richemont, Micron Technology...
23/04	Le bric-à-brac de Zonebourse : Tesla (et ARKK) dans le creux de la vague, UCB et le FTSE sur la crête

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

UCB : Acquisition of own shares	31/05	PU
UCB : Commitment to Innovation in Drug Development	29/05	PU
UCB : announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa	23/05	PU
UCB - Acquisition of own shares	20/05	AQ
UCB : Transparency notification Wellington	17/05	PU
UCB : Acquisition of own shares	17/05	PU
UCB - Acquisition of own shares	13/05	AQ
UCB : Acquisition of own shares	10/05	PU
UCB presents final open-label extension F data at International Child Neurology Congress Annual Meeting	09/05	AQ
UCB : presents final open-label extension F®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting	08/05	PU
UCB : presents final open-label extension FINTEPLA®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting	08/05	PU
UCB - Acquisition of own shares	06/05	AQ
UCB : Acquisition of own shares	26/04	PU
Pioneering innovation, fueling growth: UCB's commitment to delivering differentiated solutions	26/04	PU
UCB : General Meeting of Shareholders 2024	25/04	PU
UCB : receives European Commission approval for BIMZELX▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa	22/04	PU
UCB : FINTEPLA▼ (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)	17/04	PU
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology Annual Meeting	15/04	AQ
UCB : Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY▼ (romosozumab) can help to close the treatment gap in osteoporosi	12/04	PU
UCB : presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting	12/04	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

UCB : UCB prêt à atteindre de nouveaux sommets

Le 08 mars 2024 à 17:10